Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Swift

Showing results (261-270 of 307) with videos related to

Pageof 31
Sort By:
European Radiology|October 14, 2003
Hyperpolarized 3-helium MR imaging of the lungs: testing the concept of a central production facilityE J R van Beek, J Schmiedeskamp, J M Wild, et al.
British Journal of Haematology|November 23, 2017
Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myelomaAlexa Cohen, Tanya M Spektor, Laura Stampleman, et al.
Biorxiv : the Preprint Server for Biology|February 9, 2026
The RNA-binding protein Imp1 promotes a Spdef transcriptional program and mucus fucosylation during necrotizing enterocolitisKevin A Swift, Alexandria J Shumway, Molly Aloia, et al.
British Journal of Haematology|November 16, 2012
Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myelomaJames R Berenson, Ori Yellin, Alberto Bessudo, et al.
Arthritis and Rheumatism|January 22, 2000
Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritisA M Badger, D E Griswold, R Kapadia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2020
A Phase I Study of Ruxolitinib, Lenalidomide, and Steroids for Patients with Relapsed/Refractory Multiple MyelomaJames R Berenson, Jennifer To, Tanya M Spektor, et al.
Hematological Oncology|August 10, 2022
A phase 1 study of ruxolitinib, steroids and lenalidomide for relapsed/refractory multiple myeloma patientsJames R Berenson, Clara Kim, Sean Bujarski, et al.
Haematologica|December 31, 2016
Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patientsMichael Ghermezi, Mingjie Li, Suzie Vardanyan, et al.
Experimental Hematology|April 13, 2022
A phase 1/2 study of ixazomib in place of bortezomib or carfilzomib in a subsequent line of therapy for patients with multiple myeloma refractory to their last bortezomib or carfilzomib combination regimenDavid Daniely, Eli Forouzan, Tanya M Spektor, et al.
Annals of Hematology|October 19, 2013
A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myelomaJames R Berenson, James D Hilger, Ori Yellin, et al.
Pageof 31

Showing results (261-270 of 307) with videos related to

Sort By:
Pageof 31
European Radiology|October 14, 2003
Hyperpolarized 3-helium MR imaging of the lungs: testing the concept of a central production facilityE J R van Beek, J Schmiedeskamp, J M Wild, et al.
British Journal of Haematology|November 23, 2017
Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myelomaAlexa Cohen, Tanya M Spektor, Laura Stampleman, et al.
Biorxiv : the Preprint Server for Biology|February 9, 2026
The RNA-binding protein Imp1 promotes a Spdef transcriptional program and mucus fucosylation during necrotizing enterocolitisKevin A Swift, Alexandria J Shumway, Molly Aloia, et al.
British Journal of Haematology|November 16, 2012
Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myelomaJames R Berenson, Ori Yellin, Alberto Bessudo, et al.
Arthritis and Rheumatism|January 22, 2000
Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritisA M Badger, D E Griswold, R Kapadia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2020
A Phase I Study of Ruxolitinib, Lenalidomide, and Steroids for Patients with Relapsed/Refractory Multiple MyelomaJames R Berenson, Jennifer To, Tanya M Spektor, et al.
Hematological Oncology|August 10, 2022
A phase 1 study of ruxolitinib, steroids and lenalidomide for relapsed/refractory multiple myeloma patientsJames R Berenson, Clara Kim, Sean Bujarski, et al.
Haematologica|December 31, 2016
Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patientsMichael Ghermezi, Mingjie Li, Suzie Vardanyan, et al.
Experimental Hematology|April 13, 2022
A phase 1/2 study of ixazomib in place of bortezomib or carfilzomib in a subsequent line of therapy for patients with multiple myeloma refractory to their last bortezomib or carfilzomib combination regimenDavid Daniely, Eli Forouzan, Tanya M Spektor, et al.
Annals of Hematology|October 19, 2013
A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myelomaJames R Berenson, James D Hilger, Ori Yellin, et al.
Pageof 31